document type sequence filename description exhibit text html head title exhibit title head body bgcolor white style margin margin bottom font size font family time roman align right exhibit style margin margin bottom font size font family time roman align center confidential material omitted filed separately with security exchange commission style margin margin bottom font size font family time roman align center denotes omission style margin margin bottom font size font family time roman align center third amendment style margin margin bottom font size font family time roman align center style margin margin bottom font size font family time roman align center discovery development style margin margin bottom font size font family time roman align center collaboration license agreement style margin margin bottom text indent font size font family time roman this third amendment discovery development collaboration license agreement third amendment entered into july nbsp third amendment effective date between agio pharmaceutical agio celgene corporation celgene agio celgene each referred herein individually party collectively party capitalized term used this third amendment otherwise defined herein shall have meaning forth agreement reference section article herein reference section article agreement style margin margin bottom font size font family time roman align center introduction style margin margin bottom text indent font size font family time roman celgene agio party that certain discovery development collaboration license agreement dated april nbsp twice amended october nbsp agreement style margin margin bottom text indent font size font family time roman pursuant agreement party have engaged collaboration that applies agio expertise technology discovery validation novel target primarily cancer metabolism target discovery development associated therapeutic primarily oncology field provides development commercialization such therapeutic style margin margin bottom text indent font size font family time roman party wish amend agreement order allow more flexibility design conduct phase study additional nonclinical clinical activity that agio agrees perform celgene request providing celgene development cost incurred agio performing such activity celgene request clarifying mechanism payment such development cost style margin margin bottom text indent font size font family time roman therefore consideration covenant agreement contained herein other valuable consideration receipt adequacy which hereby acknowledged agio celgene agree follows style margin margin bottom text indent font size font family time roman amendment section nbsp section nbsp hereby amended restated entirety read follows style margin margin bottom text indent font size font family time roman development cost initiation date mean nbsp with respect commercialized program which celgene exercise celgene program option acceptance nbsp with respect commercialized program which celgene exercise celgene program option completion phase nbsp with respect commercialized program which celgene exercise celgene program option early under section nbsp nbsp with respect program nbsp with respect picked validated program selected celgene nbsp with respect split program style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman amendment section nbsp section nbsp hereby amended following such section style margin margin bottom margin left font size font family time roman addition celgene request that agio perform phase study additional activity pursuant section nbsp with respect development candidate shall have oversight over such phase study such additional activity such development candidate related discovery program style margin margin bottom text indent font size font family time roman amendment section nbsp section nbsp hereby amended section nbsp list cross reference such section nbsp with being added between style margin margin bottom text indent font size font family time roman amendment restatement section nbsp section nbsp hereby amended restated entirety read follows style margin margin bottom margin left text indent font size font family time roman celgene within such celgene option exercise period provide agio written notice that celgene elect that agio conduct first phase study development candidate such event agio shall responsible conducting first phase study with respect such development candidate under protocol approved mutual consent that meet phase protocol criterion additional clinical nonclinical activity that agio agrees perform celgene request under development plan pursuant development budget that been approved pursuant section nbsp unless program becomes split program celgene shall obligated phase amount development cost with respect thereto pursuant section nbsp upon agio completion such first phase study agio shall deliver celgene final written report that meet phase report criterion within celgene receipt such written report celgene reasonably request that agio provide additional information access record extent available agio such time disclosed part regular update under section nbsp nbsp under section nbsp this section nbsp with respect such phase study with respect other development candidate that undergoing enabling study later stage development under different program within following completion phase nbsp such additional information access such period extended celgene option exercise period either celgene option exercise period celgene option exercise period referred celgene option exercise period celgene provide agio written notice election exercise celgene program option which event provision section nbsp shall apply style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman amendment restatement section nbsp section nbsp hereby amended restated entirety read follows style margin margin bottom margin left text indent font size font family time roman development under each commercialized program split program program shall governed development plan development plan that describes proposed overall objective such licensed program well activity performed party responsible performance activity which shall provided section nbsp budget development cost development budget anticipated timeline performance provided that development budget will only applicable period following development cost initiation date such licensed program addition celgene request that agio perform development activity celgene picked validated program agio consent perform such activity that agio perform phase study additional activity pursuant section nbsp such activity shall also governed development plan with development budget provided that development budget such phase study additional activity pursuant section nbsp must approved except that celgene shall have final decision making authority with respect dispute regarding development budget such phase study additional activity commercialized program style margin margin bottom text indent font size font family time roman amendment section nbsp section nbsp hereby amended following such section style margin margin bottom margin left font size font family time roman notwithstanding above event phase study under split program includes disease specific expansion cohort that initial phase study disease specific expansion cohort shall support initiation subsequent pivotal clinical trial principal purpose which nbsp designed establish that product acceptable safety efficacy profile intended determine warning precaution adverse reaction that associated with such product dosage range prescribed nbsp registration trial intended support filing application regulatory approval such compound territory pivotal trial then upon under pivotal trial celgene shall agio milestone payment amount equal lesser nbsp million dollar nbsp fifty percent nbsp cost expense disease specific expansion cohort including analysis clinical sample clinical trial product supply that actually incurred behalf agio specifically identifiable specifically allocable such disease specific expansion cohort disease specific expansion cohort milestone payment such disease specific expansion cohort milestone payment shall made within after celgene receipt appropriate invoice unless otherwise agreed mutual consent maximum amount disease specific expansion cohort milestone payment payable under split program will million dollar regardless number disease specific expansion cohort pivotal trial under split program style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman event phase study under split program already includes disease specific expansion cohort mutual consent agrees amend phase study include phase study with larger patient population same disease specific indication then development cost initiation date shall begin upon style margin margin bottom text indent font size font family time roman amendment section nbsp section nbsp hereby amended append following phrase sentence except extent such manufacturing cost included development cost payable celgene pursuant section nbsp connection with phase study additional activity performed agio pursuant section nbsp style margin margin bottom text indent font size font family time roman amendment restatement section nbsp section nbsp hereby amended restated entirety read follows style margin margin bottom margin left text indent font size font family time roman payment commercialized program following celgene selection development candidate selection stage under commercialized program pursuant section nbsp program program basis celgene shall agio twenty million five hundred thousand dollar amount upon acceptance achieved agio such development candidate such commercialized program pursuant section nbsp provided that nbsp such amount will with respect first nbsp acceptance achieved agio under commercialized program which acceptance achieved nbsp such amount will prior nbsp such amount will with respect acceptance achieved agio under optionable program that becomes split program pursuant section nbsp clarity celgene shall amount with respect picked validated program selected celgene program whether celgene party agio style margin margin bottom text indent font size font family time roman amendment restatement section nbsp section nbsp hereby amended restated entirety read follows style margin margin bottom margin left text indent font size font family time roman licensed program phase study except forth clause nbsp nbsp below with respect split program program following shall apply commercialized program celgene picked validated program phase study pursuant section nbsp style margin margin bottom margin left text indent font size font family time roman with respect each commercialized program picked validated program selected celgene under which agio performs development activity hereunder celgene shall responsible bearing hundred percent nbsp development cost such licensed program including development cost clinical trial other licensed program activity conducted agio celgene request pursuant section nbsp agreed agio that nbsp incurred after development cost initiation date such program nbsp within percent nbsp approved development budget style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman under development plan such program notwithstanding anything herein contrary cost first phase study conducted agio pursuant section nbsp shall included development cost under this section nbsp shall addressed section nbsp style margin margin bottom margin left text indent font size font family time roman celgene request that agio perform first phase study additional activity pursuant section nbsp unless applicable program becomes split program then upon earlier nbsp determination first maximum tolerated dose development candidate agio determination option exercise date celgene shall agio milestone payment amount equal greater nbsp five million dollar nbsp hundred percent nbsp development cost such phase study conducted agio that nbsp incurred such phase study earlier determination option exercise date nbsp within percent nbsp approved development budget under development plan such phase study phase amount phase amount shall payable within nbsp following earlier celgene receipt written notice determination option exercise date subsequent earlier determination option exercise date celgene shall responsible bearing hundred percent nbsp development cost remaining phase such phase study that nbsp incurred such phase study nbsp within percent nbsp approved development budget under development plan such phase study clarity celgene shall responsible phase amount development cost phase study conducted agio pursuant section nbsp with respect split program style margin margin bottom margin left text indent font size font family time roman within nbsp following beginning each agio shall prepare deliver celgene report detailing development cost incurred during such detailing budget estimate budget estimate remaining such with respect which celgene required pursuant section nbsp agio shall submit supporting information reasonably requested celgene related such development cost included agio report within nbsp after agio receipt such request celgene shall amount such development cost within nbsp following later celgene receipt such report celgene receipt such supporting information within nbsp following each agio shall prepare deliver celgene reconciliation report detailing difference between development cost incurred during such with respect which celgene required pursuant section nbsp budget estimate same period agio shall submit supporting information reasonably requested celgene related such development cost included agio reconciliation report within nbsp after agio receipt such request celgene shall unpaid amount development cost identified such reconciliation report within nbsp following later celgene receipt such reconciliation report celgene receipt such supporting style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman information associated therewith overpayment identified such reconciliation report shall credited towards payment obligation celgene pursuant section nbsp nbsp following calendar quarter style margin margin bottom text indent font size font family time roman additional conforming amendment style margin margin bottom margin left text indent font size font family time roman section nbsp hereby amended replace table phase amount with following style margin margin bottom margin left text indent font size font family time roman phase amount nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp style margin margin bottom margin left text indent font size font family time roman each reference agreement section nbsp hereby replaced with reference section nbsp style margin margin bottom margin left text indent font size font family time roman section nbsp hereby amended replace reference section nbsp with reference section nbsp style margin margin bottom text indent font size font family time roman incorporation article hereby incorporated mutatis mutandis into this third amendment style margin margin bottom text indent font size font family time roman effect agreement except specifically amended this third amendment agreement will remain full force effect hereby ratified confirmed extent conflict arises between term agreement this third amendment term this third amendment shall prevail only extent necessary accomplish their intended purpose style margin margin bottom font size font family time roman align center remainder page intentionally left blank style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman witness whereof party have executed this third amendment third amendment effective date style font size margin margin bottom nbsp align right table cellspacing cellpadding width border style border collapse collapse font family time roman font size width valign bottom width width style font family time roman font size valign colspan agio pharmaceutical style font size height height colspan style font family time roman font size valign valign bottom valign style margin margin bottom border bottom solid font size font family time roman david schenkein style font family time roman font size valign title valign bottom valign style margin margin bottom border bottom solid font size font family time roman style font size height colspan style font family time roman font size valign colspan celgene corporation style font size height height colspan style font family time roman font size valign valign bottom valign style margin margin bottom border bottom solid font size font family time roman thomas daniel style font family time roman font size valign title valign bottom valign style margin margin bottom border bottom solid font size font family time roman president table style font size margin margin bottom nbsp align right table cellspacing cellpadding width border style border collapse collapse font family time roman font size width valign bottom width width style font family time roman font size valign celgene nbsp legal valign bottom valign table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center body html text document